Current status on the therapeutic strategies for heart failure and diabetic cardiomyopathy
Heart failure (HF) is a leading cause of disease and death from cardiovascular diseases, with cardiovascular diseases accounting for the highest cases of deaths worldwide. The reality is that the quality-of-life survival for those suffering HF remains poor with 45–60% reported deaths within five yea...
Guardado en:
Autores principales: | Amy Hyein Kim, Jung Eun Jang, Jin Han |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Elsevier
2022
|
Materias: | |
Acceso en línea: | https://doaj.org/article/6c96c6a6dfa849b295491abd86c3735f |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Recent and Upcoming Drug Therapies for Pediatric Heart Failure
por: Karla L. Loss, et al.
Publicado: (2021) -
Potential Mechanisms of SGLT2 Inhibitors for the Treatment of Heart Failure With Preserved Ejection Fraction
por: Steffen Pabel, et al.
Publicado: (2021) -
The Prognostic Value of Lung Ultrasound in Patients With Newly Diagnosed Heart Failure With Preserved Ejection Fraction in the Ambulatory Setting
por: Blanka Morvai-Illés, et al.
Publicado: (2021) -
A study of association between heart failure with preserved ejection fraction with hypertension and diabetes mellitus
por: Swapan Sarkar, et al.
Publicado: (2021) -
Nonalcoholic Fatty Liver Disease and Risk of Heart Failure Among Medicare Beneficiaries
por: Marat Fudim, et al.
Publicado: (2021)